▶ 調査レポート

ペプチド心血管治療薬の世界市場(~2026年)

• 英文タイトル:Global Peptide Based Cardiovascular Therapeutics Market Size, Status and Forecast 2020-2026

QYResearchが調査・発行した産業分析レポートです。ペプチド心血管治療薬の世界市場(~2026年) / Global Peptide Based Cardiovascular Therapeutics Market Size, Status and Forecast 2020-2026 / MRC2-11QY04204資料のイメージです。• レポートコード:MRC2-11QY04204
• 出版社/出版日:QYResearch / 2020年11月20日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、96ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:ヘルスケア
• 販売価格(消費税別)
  Single User¥577,200 (USD3,900)▷ お問い合わせ
  Multi User¥865,800 (USD5,850)▷ お問い合わせ
  Enterprise License¥1,154,400 (USD7,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料はペプチド心血管治療薬のグローバル市場について調査・分析したレポートです。種類別(ビバリルジン、エプチフィバチド、その他)市場規模、用途別(病院薬局、小売薬局、オンライン薬局)市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別ペプチド心血管治療薬の競争状況、市場シェア
・世界のペプチド心血管治療薬市場:種類別市場規模 2015年-2020年(ビバリルジン、エプチフィバチド、その他)
・世界のペプチド心血管治療薬市場:種類別市場規模予測 2021年-2026年(ビバリルジン、エプチフィバチド、その他)
・世界のペプチド心血管治療薬市場:用途別市場規模 2015年-2020年(病院薬局、小売薬局、オンライン薬局)
・世界のペプチド心血管治療薬市場:用途別市場規模予測 2021年-2026年(病院薬局、小売薬局、オンライン薬局)
・北米のペプチド心血管治療薬市場分析:米国、カナダ
・ヨーロッパのペプチド心血管治療薬市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアのペプチド心血管治療薬市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米のペプチド心血管治療薬市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカのペプチド心血管治療薬市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Pfizer、AstraZeneca、Novartis、Ipsen、Merck、Mylan、Fresenius、Apotex Holdings、Novetide、Amneal Pharmaceuticals、Dr. Reddy's Laboratories
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. Cardiovascular disease includes coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack). Other CVDs include stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis.

Market Analysis and Insights: Global Peptide Based Cardiovascular Therapeutics Market
The global Peptide Based Cardiovascular Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Peptide Based Cardiovascular Therapeutics Scope and Market Size
Peptide Based Cardiovascular Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Peptide Based Cardiovascular Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Pfizer
AstraZeneca
Novartis
Ipsen
Merck
Mylan
Fresenius
Apotex Holdings
Novetide
Amneal Pharmaceuticals
Dr. Reddy’s Laboratories

Market segment by Type, the product can be split into
Bivalirudin
Eptifibatide
Others
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Peptide Based Cardiovascular Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Peptide Based Cardiovascular Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Bivalirudin
1.4.3 Eptifibatide
1.4.4 Others
1.5 Market by Application
1.5.1 Global Peptide Based Cardiovascular Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Peptide Based Cardiovascular Therapeutics Market Perspective (2015-2026)
2.2 Global Peptide Based Cardiovascular Therapeutics Growth Trends by Regions
2.2.1 Peptide Based Cardiovascular Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Peptide Based Cardiovascular Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Peptide Based Cardiovascular Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Peptide Based Cardiovascular Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Peptide Based Cardiovascular Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Peptide Based Cardiovascular Therapeutics Players by Market Size
3.1.1 Global Top Peptide Based Cardiovascular Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Peptide Based Cardiovascular Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Peptide Based Cardiovascular Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Peptide Based Cardiovascular Therapeutics Market Concentration Ratio
3.2.1 Global Peptide Based Cardiovascular Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Peptide Based Cardiovascular Therapeutics Revenue in 2019
3.3 Peptide Based Cardiovascular Therapeutics Key Players Head office and Area Served
3.4 Key Players Peptide Based Cardiovascular Therapeutics Product Solution and Service
3.5 Date of Enter into Peptide Based Cardiovascular Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Peptide Based Cardiovascular Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Peptide Based Cardiovascular Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Peptide Based Cardiovascular Therapeutics Market Size by Application (2015-2020)
5.2 Global Peptide Based Cardiovascular Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Peptide Based Cardiovascular Therapeutics Market Size (2015-2020)
6.2 Peptide Based Cardiovascular Therapeutics Key Players in North America (2019-2020)
6.3 North America Peptide Based Cardiovascular Therapeutics Market Size by Type (2015-2020)
6.4 North America Peptide Based Cardiovascular Therapeutics Market Size by Application (2015-2020)

7 Europe
7.1 Europe Peptide Based Cardiovascular Therapeutics Market Size (2015-2020)
7.2 Peptide Based Cardiovascular Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Peptide Based Cardiovascular Therapeutics Market Size by Type (2015-2020)
7.4 Europe Peptide Based Cardiovascular Therapeutics Market Size by Application (2015-2020)

8 China
8.1 China Peptide Based Cardiovascular Therapeutics Market Size (2015-2020)
8.2 Peptide Based Cardiovascular Therapeutics Key Players in China (2019-2020)
8.3 China Peptide Based Cardiovascular Therapeutics Market Size by Type (2015-2020)
8.4 China Peptide Based Cardiovascular Therapeutics Market Size by Application (2015-2020)

9 Japan
9.1 Japan Peptide Based Cardiovascular Therapeutics Market Size (2015-2020)
9.2 Peptide Based Cardiovascular Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Peptide Based Cardiovascular Therapeutics Market Size by Type (2015-2020)
9.4 Japan Peptide Based Cardiovascular Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Peptide Based Cardiovascular Therapeutics Market Size (2015-2020)
10.2 Peptide Based Cardiovascular Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Peptide Based Cardiovascular Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Peptide Based Cardiovascular Therapeutics Market Size by Application (2015-2020)

11 India
11.1 India Peptide Based Cardiovascular Therapeutics Market Size (2015-2020)
11.2 Peptide Based Cardiovascular Therapeutics Key Players in India (2019-2020)
11.3 India Peptide Based Cardiovascular Therapeutics Market Size by Type (2015-2020)
11.4 India Peptide Based Cardiovascular Therapeutics Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Peptide Based Cardiovascular Therapeutics Market Size (2015-2020)
12.2 Peptide Based Cardiovascular Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Peptide Based Cardiovascular Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Peptide Based Cardiovascular Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Peptide Based Cardiovascular Therapeutics Introduction
13.1.4 Pfizer Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 AstraZeneca
13.2.1 AstraZeneca Company Details
13.2.2 AstraZeneca Business Overview
13.2.3 AstraZeneca Peptide Based Cardiovascular Therapeutics Introduction
13.2.4 AstraZeneca Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020)
13.2.5 AstraZeneca Recent Development
13.3 Novartis
13.3.1 Novartis Company Details
13.3.2 Novartis Business Overview
13.3.3 Novartis Peptide Based Cardiovascular Therapeutics Introduction
13.3.4 Novartis Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020)
13.3.5 Novartis Recent Development
13.4 Ipsen
13.4.1 Ipsen Company Details
13.4.2 Ipsen Business Overview
13.4.3 Ipsen Peptide Based Cardiovascular Therapeutics Introduction
13.4.4 Ipsen Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020)
13.4.5 Ipsen Recent Development
13.5 Merck
13.5.1 Merck Company Details
13.5.2 Merck Business Overview
13.5.3 Merck Peptide Based Cardiovascular Therapeutics Introduction
13.5.4 Merck Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020)
13.5.5 Merck Recent Development
13.6 Mylan
13.6.1 Mylan Company Details
13.6.2 Mylan Business Overview
13.6.3 Mylan Peptide Based Cardiovascular Therapeutics Introduction
13.6.4 Mylan Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020)
13.6.5 Mylan Recent Development
13.7 Fresenius
13.7.1 Fresenius Company Details
13.7.2 Fresenius Business Overview
13.7.3 Fresenius Peptide Based Cardiovascular Therapeutics Introduction
13.7.4 Fresenius Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020)
13.7.5 Fresenius Recent Development
13.8 Apotex Holdings
13.8.1 Apotex Holdings Company Details
13.8.2 Apotex Holdings Business Overview
13.8.3 Apotex Holdings Peptide Based Cardiovascular Therapeutics Introduction
13.8.4 Apotex Holdings Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020)
13.8.5 Apotex Holdings Recent Development
13.9 Novetide
13.9.1 Novetide Company Details
13.9.2 Novetide Business Overview
13.9.3 Novetide Peptide Based Cardiovascular Therapeutics Introduction
13.9.4 Novetide Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020)
13.9.5 Novetide Recent Development
13.10 Amneal Pharmaceuticals
13.10.1 Amneal Pharmaceuticals Company Details
13.10.2 Amneal Pharmaceuticals Business Overview
13.10.3 Amneal Pharmaceuticals Peptide Based Cardiovascular Therapeutics Introduction
13.10.4 Amneal Pharmaceuticals Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020)
13.10.5 Amneal Pharmaceuticals Recent Development
13.11 Dr. Reddy’s Laboratories
10.11.1 Dr. Reddy’s Laboratories Company Details
10.11.2 Dr. Reddy’s Laboratories Business Overview
10.11.3 Dr. Reddy’s Laboratories Peptide Based Cardiovascular Therapeutics Introduction
10.11.4 Dr. Reddy’s Laboratories Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020)
10.11.5 Dr. Reddy’s Laboratories Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Peptide Based Cardiovascular Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Peptide Based Cardiovascular Therapeutics Revenue
Table 3. Ranking of Global Top Peptide Based Cardiovascular Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Peptide Based Cardiovascular Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Bivalirudin
Table 6. Key Players of Eptifibatide
Table 7. Key Players of Others
Table 8. Global Peptide Based Cardiovascular Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Peptide Based Cardiovascular Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Peptide Based Cardiovascular Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Peptide Based Cardiovascular Therapeutics Market Share by Regions (2015-2020)
Table 12. Global Peptide Based Cardiovascular Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Peptide Based Cardiovascular Therapeutics Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Peptide Based Cardiovascular Therapeutics Market Growth Strategy
Table 18. Main Points Interviewed from Key Peptide Based Cardiovascular Therapeutics Players
Table 19. Global Peptide Based Cardiovascular Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 20. Global Peptide Based Cardiovascular Therapeutics Market Share by Players (2015-2020)
Table 21. Global Top Peptide Based Cardiovascular Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptide Based Cardiovascular Therapeutics as of 2019)
Table 22. Global Peptide Based Cardiovascular Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Peptide Based Cardiovascular Therapeutics Product Solution and Service
Table 25. Date of Enter into Peptide Based Cardiovascular Therapeutics Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Peptide Based Cardiovascular Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 28. Global Peptide Based Cardiovascular Therapeutics Market Size Share by Type (2015-2020)
Table 29. Global Peptide Based Cardiovascular Therapeutics Revenue Market Share by Type (2021-2026)
Table 30. Global Peptide Based Cardiovascular Therapeutics Market Size Share by Application (2015-2020)
Table 31. Global Peptide Based Cardiovascular Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 32. Global Peptide Based Cardiovascular Therapeutics Market Size Share by Application (2021-2026)
Table 33. North America Key Players Peptide Based Cardiovascular Therapeutics Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Peptide Based Cardiovascular Therapeutics Market Share (2019-2020)
Table 35. North America Peptide Based Cardiovascular Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 36. North America Peptide Based Cardiovascular Therapeutics Market Share by Type (2015-2020)
Table 37. North America Peptide Based Cardiovascular Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 38. North America Peptide Based Cardiovascular Therapeutics Market Share by Application (2015-2020)
Table 39. Europe Key Players Peptide Based Cardiovascular Therapeutics Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Peptide Based Cardiovascular Therapeutics Market Share (2019-2020)
Table 41. Europe Peptide Based Cardiovascular Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Peptide Based Cardiovascular Therapeutics Market Share by Type (2015-2020)
Table 43. Europe Peptide Based Cardiovascular Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Peptide Based Cardiovascular Therapeutics Market Share by Application (2015-2020)
Table 45. China Key Players Peptide Based Cardiovascular Therapeutics Revenue (2019-2020) (Million US$)
Table 46. China Key Players Peptide Based Cardiovascular Therapeutics Market Share (2019-2020)
Table 47. China Peptide Based Cardiovascular Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 48. China Peptide Based Cardiovascular Therapeutics Market Share by Type (2015-2020)
Table 49. China Peptide Based Cardiovascular Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 50. China Peptide Based Cardiovascular Therapeutics Market Share by Application (2015-2020)
Table 51. Japan Key Players Peptide Based Cardiovascular Therapeutics Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Peptide Based Cardiovascular Therapeutics Market Share (2019-2020)
Table 53. Japan Peptide Based Cardiovascular Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Peptide Based Cardiovascular Therapeutics Market Share by Type (2015-2020)
Table 55. Japan Peptide Based Cardiovascular Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Peptide Based Cardiovascular Therapeutics Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Peptide Based Cardiovascular Therapeutics Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Peptide Based Cardiovascular Therapeutics Market Share (2019-2020)
Table 59. Southeast Asia Peptide Based Cardiovascular Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Peptide Based Cardiovascular Therapeutics Market Share by Type (2015-2020)
Table 61. Southeast Asia Peptide Based Cardiovascular Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Peptide Based Cardiovascular Therapeutics Market Share by Application (2015-2020)
Table 63. India Key Players Peptide Based Cardiovascular Therapeutics Revenue (2019-2020) (Million US$)
Table 64. India Key Players Peptide Based Cardiovascular Therapeutics Market Share (2019-2020)
Table 65. India Peptide Based Cardiovascular Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 66. India Peptide Based Cardiovascular Therapeutics Market Share by Type (2015-2020)
Table 67. India Peptide Based Cardiovascular Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 68. India Peptide Based Cardiovascular Therapeutics Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Peptide Based Cardiovascular Therapeutics Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Peptide Based Cardiovascular Therapeutics Market Share (2019-2020)
Table 71. Central & South America Peptide Based Cardiovascular Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Peptide Based Cardiovascular Therapeutics Market Share by Type (2015-2020)
Table 73. Central & South America Peptide Based Cardiovascular Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Peptide Based Cardiovascular Therapeutics Market Share by Application (2015-2020)
Table 75. Pfizer Company Details
Table 76. Pfizer Business Overview
Table 77. Pfizer Product
Table 78. Pfizer Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020) (Million US$)
Table 79. Pfizer Recent Development
Table 80. AstraZeneca Company Details
Table 81. AstraZeneca Business Overview
Table 82. AstraZeneca Product
Table 83. AstraZeneca Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020) (Million US$)
Table 84. AstraZeneca Recent Development
Table 85. Novartis Company Details
Table 86. Novartis Business Overview
Table 87. Novartis Product
Table 88. Novartis Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020) (Million US$)
Table 89. Novartis Recent Development
Table 90. Ipsen Company Details
Table 91. Ipsen Business Overview
Table 92. Ipsen Product
Table 93. Ipsen Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020) (Million US$)
Table 94. Ipsen Recent Development
Table 95. Merck Company Details
Table 96. Merck Business Overview
Table 97. Merck Product
Table 98. Merck Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020) (Million US$)
Table 99. Merck Recent Development
Table 100. Mylan Company Details
Table 101. Mylan Business Overview
Table 102. Mylan Product
Table 103. Mylan Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020) (Million US$)
Table 104. Mylan Recent Development
Table 105. Fresenius Company Details
Table 106. Fresenius Business Overview
Table 107. Fresenius Product
Table 108. Fresenius Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020) (Million US$)
Table 109. Fresenius Recent Development
Table 110. Apotex Holdings Business Overview
Table 111. Apotex Holdings Product
Table 112. Apotex Holdings Company Details
Table 113. Apotex Holdings Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020) (Million US$)
Table 114. Apotex Holdings Recent Development
Table 115. Novetide Company Details
Table 116. Novetide Business Overview
Table 117. Novetide Product
Table 118. Novetide Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020) (Million US$)
Table 119. Novetide Recent Development
Table 120. Amneal Pharmaceuticals Company Details
Table 121. Amneal Pharmaceuticals Business Overview
Table 122. Amneal Pharmaceuticals Product
Table 123. Amneal Pharmaceuticals Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020) (Million US$)
Table 124. Amneal Pharmaceuticals Recent Development
Table 125. Dr. Reddy's Laboratories Company Details
Table 126. Dr. Reddy's Laboratories Business Overview
Table 127. Dr. Reddy's Laboratories Product
Table 128. Dr. Reddy's Laboratories Revenue in Peptide Based Cardiovascular Therapeutics Business (2015-2020) (Million US$)
Table 129. Dr. Reddy's Laboratories Recent Development
Table 130. Research Programs/Design for This Report
Table 131. Key Data Information from Secondary Sources
Table 132. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peptide Based Cardiovascular Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Bivalirudin Features
Figure 3. Eptifibatide Features
Figure 4. Others Features
Figure 5. Global Peptide Based Cardiovascular Therapeutics Market Share by Application: 2020 VS 2026
Figure 6. Hospital Pharmacies Case Studies
Figure 7. Retail Pharmacies Case Studies
Figure 8. Online Pharmacies Case Studies
Figure 9. Peptide Based Cardiovascular Therapeutics Report Years Considered
Figure 10. Global Peptide Based Cardiovascular Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Peptide Based Cardiovascular Therapeutics Market Share by Regions: 2020 VS 2026
Figure 12. Global Peptide Based Cardiovascular Therapeutics Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Peptide Based Cardiovascular Therapeutics Market Share by Players in 2019
Figure 15. Global Top Peptide Based Cardiovascular Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptide Based Cardiovascular Therapeutics as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Peptide Based Cardiovascular Therapeutics Revenue in 2019
Figure 17. North America Peptide Based Cardiovascular Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Peptide Based Cardiovascular Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Peptide Based Cardiovascular Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Peptide Based Cardiovascular Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Peptide Based Cardiovascular Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Peptide Based Cardiovascular Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Peptide Based Cardiovascular Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed